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Abstract: Far-red fluorescent reporter genes can be used for tracking cells non-invasively in vivo
using fluorescence imaging. Here, we investigate the effectiveness of the far-red fluorescent protein,
E2-Crimson (E2C), for tracking mouse embryonic cells (mESCs) in vivo following subcutaneous
administration into mice. Using a knock-in strategy, we introduced E2C into the Rosa26 locus of
an E14-Bra-GFP mESC line, and after confirming that the E2C had no obvious effect on the phenotype
of the mESCs, we injected them into mice and imaged them over nine days. The results showed that
fluorescence intensity was weak, and cells could only be detected when injected at high densities.
Furthermore, intensity peaked on day 4 and then started to decrease, despite the fact that tumour
volume continued to increase beyond day 4. Histopathological analysis showed that although E2C
fluorescence could barely be detected in vivo at day 9, analysis of frozen sections indicated that all
mESCs within the tumours continued to express E2C. We hypothesise that the decrease in fluorescence
intensity in vivo was probably due to the fact that the mESC tumours became more vascular with
time, thus leading to increased absorbance of E2C fluorescence by haemoglobin. We conclude that
the E2C reporter has limited use for tracking cells in vivo, at least when introduced as a single copy
into the Rosa26 locus.
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1. Introduction
During the past two decades, considerable advances have been made in the field of fluorescent
imaging technology, especially with regard to fluorescent reporter genes, which are particularly useful
because they facilitate long-term cell tracking. In vivo optical imaging enables the study of living
organisms by monitoring and characterising physical and biological processes within specific cells or
tissues of interest. Fluorescence-based labelling serves as an ideal tool for in vivo imaging in animals.
However, due to the photon absorption by tissue haemoglobin (<650 nm wavelength region) and
water (>900 nm wavelength region), the majority of visible fluorescence (e.g., green fluorescent protein
(GFP) green emitted light) is absorbed within 500 µm of the surface tissue of the recipient animal.
To circumvent this, an optical window of approximately 650–900 nm of the near infra-red wavelength
region of the spectrum is favourable, which allows maximum depth of fluorescence penetration [1].
In addition, cell nuclei and mitochondria cause light scattering within the optical window [2], whereas
the intensity can be reduced by using longer wavelengths [3]. This requires fluorescent probes that have
emission spectra within the far-red region (710–850 nm wavelength, which is part of the near-infrared
spectrum). E2-Crimson (E2C) is a tetramer derived from DsRed-Express2 with the advantages of fast
maturation, high solubility, high photostability and low cytotoxicity. Furthermore, the excitation and
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emission maxima of E2C are 611 and 646 nm, respectively. This means that it can be excited efficiently
by standard far-red lasers routinely used in optical instruments, making it suitable for tracking cells
in vivo [4].
Mouse embryonic stem cells (mESCs) have served as invaluable tools for understanding the
cellular and molecular mechanisms that regulate mammalian development, and for determining
the signalling pathways required for the differentiation of specific cell lineages [5–7]. In order to
achieve long-term cell tracking, many transgenic mESC lines have been established by using viral
transduction of fluorescent reporter genes [8–13]. However, the random insertion of reporter genes
into chromosomes results in different gene copy numbers and integration sites [11,14,15]. Furthermore,
despite the fact that this approach can lead to higher expression levels due to the presence of multiple
copies of the transgene, the levels of expression can vary considerably between different cells within
the transduced population [9–12,16–18]. There can be a high prevalence of transcriptional silencing
of the transgene in vitro and in vivo, which may be due to DNA methylation [19–22]. There is also
evidence that transgenes introduced into mESCs via viral transduction have a tendency to be silenced
following differentiation to specific lineages [15].
Gene knock-in has provided a feasible alternative to producing transgenic mESC lines where
the plasmid vectors serve as exogenous gene carriers to incorporate the reporter genes into the
chromosomal locus of interest, subsequently leading to the disruption of the targeted locus with
constant expression of the transgene [23,24]. One of the widely-considered targeting loci is Rosa26.
Located on mouse chromosome 6, the Rosa26 locus comprises three exons spanning approximately
9 kb and generates three non-coding transcripts, one of them being a highly conserved anti-sense
RNA [25,26]. It was originally identified by Soriano’s group, who using promoter-trap screening,
integrated the β-geo (fused gene formed from the β-galactosidase (β-gal) and neomycin resistance
genes) cassette into mESCs derived from the 129Sv mouse strain via a retroviral targeting vector
named ROSAβ-gal (reverse orientation splice acceptor β-gal). The resulting mutants showed
constitutive and ubiquitous expression of a single copy of the transgene in all tissues at all pre- and
post-natal developmental stages of the germ-line chimeric mice, albeit at different levels of expression.
Moreover, none of the progeny exhibited any obvious phenotype [27]. Taken together, these reports
highlight the usefulness of Rosa26 to construct stable reporter mESC lines for tracking cells following
transplantation [28].
A common strategy for introducing transgenes into the Rosa26 locus of mESCs involves a knock-in
vector that contains the exogenous reporter gene cDNA sequence preceded by a splice acceptor
sequence, a positive selection marker (usually a neomycin resistance gene cassette), the Rosa26 5′- and
3′-homology arms (HAs) flanking the aforementioned elements, and a negative selection marker
(commonly a diphtheria toxin A subunit, DT-A). During the recombination between the Rosa26
homology arms, the transgene integrates into the first intron of Rosa26 at a specific XbaI site and is
expressed constitutively under the control of the Rosa26 promoter [25]. Using this strategy, it has been
reported that the targeting efficiency of the Rosa26 locus is around 20% of drug-resistant colonies [26,29],
or up to 45% if longer arms of homology were used [30].
Brachyury (Bra, also known as T) is the key marker of the entire primitive streak and is a pan
mesodermal marker that is expressed until the stage of tail bud formation, playing an important role
in mesoderm development [31–38]. Fehling et al. generated an E14-Bra-GFP mESC line to investigate
mesodermal differentiation in vitro. In this line, an eGFP mini gene cassette was targeted into the
Bra locus of E14.1 ESCs, replacing approximately two-thirds of exon 1 of Bra [39]. GFP expression was
under the control of the Bra promoter, which means that cells that undergo mesoderm differentiation
are marked by GFP fluorescence [39]. The GFP+ cells isolated in vitro have shown the ability to
generate mesodermal derivatives including the haematopoietic and cardiac lineages, as well as
neuromesodermal progenitors [39–42].
The aim of this study was to assess the effectiveness of the E2C reporter for in vivo imaging.
To this end, we generated a mESC line labelled with combinatorial reporters E2-Crimson and GFP
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by knocking-in the E2C transgene into the Rosa26 locus of the E14-Bra-GFP mESC line based on
Soriano’s strategy. After confirming that this genetic modification did not affect the phenotype of
the mESCs, we then injected the cells subcutaneously in mice and tracked them using non-invasive
fluorescence imaging.
2. Results
2.1. Rosa26 Knock-in of E2-Crimson Transgene and Analysis of E2C Expression in Screened Positive Clones
The Rosa26 knock-in strategy is shown in Figure 1. Following electroporation of E14-Bra-GFP
mESCs with the targeting plasmid and G418 selection, 35 colonies were expanded and analysed
by long-range PCR for correct insertion at the Rosa26 locus. Twenty-one clones showed the correct
PCR product size of approximately 3.4 kb and thus were considered positive recombinants. Positive
recombinants comprised just over 50% of the resultant clones (Figure A1).
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Figure 1. Schematic illustration of the Rosa26 knock-in strategy. (A) E14-Bra-GFP mESC Rosa26 
chromosome structure and pDest-ROSA26-E2C targeting vector. The vector contains two homology 
arms (HAs) that flank the E2-Crimson cassette, which has a polyadenylation (pA) signal, and a 
downstream positive drug selection marker neo (neomycin resistance). The insertion site in between 
the HAs is identified by the XbaI restriction enzyme site in the Rosa26 locus. A lethal negative 
selection marker DT-A is placed in the 5′ upstream region adjacent to the targeting arm. The PvuI 
restriction enzyme sites are located in the vector backbone. When linearised for gene targeting, most 
of the vector backbone is removed following PvuI restriction digestion; (B) E14-Bra-GFP mESC 
Rosa26 locus with correctly targeted insertion of linearised pDest-ROSA26-E2C targeting vector. In 
the correct recombinants, E2C cDNA is introduced into the Rosa26 locus and is expressed under the 
control of the Rosa26 promoter. A loxP site (indicated with a grey triangle) is located next to the 5′ 
HA. Flippase recombinase target (FRT) sites (indicated with grey arrow heads) flanking the neo 
cassette are designed for optional removal of the neo cassette. Grey arrows show the forward and 
reverse primer-binding sites for the PCR screen of correct homologous 3′-HA recombination. 
The 18 positive and three randomly selected negative clones were individually expanded from 
the 96-well cryopreserved plates. Viable clones were expanded and investigated for expression of E2C 
via fluorescence microscopy. Five positive clones were found to be fluorescent, and their intensity was 
comparable to that of tdTomato-transduced E14-Bra-GFP mESCs (produced in-house).  
No fluorescence signal was detected among the negative clones (Figure 2). To test whether the positive 
clones constituted homogeneous E2C-expressing cell populations, four of the E2C-expressing clones, 
namely +B5, +C4, +D1 and +E3 were selected for flow cytometry. The average E2C signal intensity of 
all 4 clones was approximately 103. For clone +C4, 99% of the population expressed E2C, indicating 
very high purity (Figure 3). +C4 was therefore selected for subsequent experiments. 
Figure 1. Schematic illustration of the Rosa26 knock-in strategy. (A) E14-Bra-GFP mESC
Rosa26 chromosom structur and pDest-ROSA26-E2C targe ing vector. The vector contains two
homology arms (HAs) that flank the E2-Crimson cassette, which has pol adenylation (pA) sign l,
and a downstream positive drug selection marker neo (neomycin resistance). The insertion site in
between the HAs is identified by the XbaI restriction enzyme site in the Rosa26 locus. A lethal negative
selection marker DT-A is placed in the 5′ upstream region adjacent to the targeting arm. The PvuI
restriction enzyme sites are located in the vector backbone. When linearised for gene targeting, most of
the vector backbone is removed following PvuI restriction digestion; (B) E14-Bra-GFP mESC Rosa26
locus with correctly targeted insertion of linearised pDest-ROSA26-E2C targeting vector. In the correct
recombinants, E2C cDNA is introduced into the Rosa26 locus and is expressed under the control
of the Rosa26 promoter. A loxP site (indicated with a grey triangle) is located next to the 5′ HA.
Flippase recombinase target (FRT) sites (indicated with grey arrow heads) flanking the neo cassette
are designed for optional removal of the n o cassette. Grey arrows show the forward d reverse
primer-bindin sites for the PCR screen of correct homologous 3′-HA recombination.
The 18 positive and three randomly selected negative clones were individually expanded from
the 96-well cryopreserved plates. Viable clones were expanded and investigated for expression
of E2C via fluorescence microscopy. Five positive clones were fou d to be fluorescent, and their
intensity was comparable to that of tdTomato-transduced E14-Bra-GFP mESCs (produced in-house).
No fluorescence signal was detected among the negative clones (Figure 2). To test whether the positive
clones constituted homogeneous E2C-expressing cell populations, four of the E2C-expressing clones,
namely +B5, +C4, +D1 and +E3 were selected for flow cytometry. The average E2C signal intensity of
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all 4 clones was approximately 103. For clone +C4, 99% of the population expressed E2C, indicating
very high purity (Figure 3). +C4 was therefore selected for subsequent experiments.Int. J. Mol. Sci. 2018, 19, 19  4 of 17 
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tdTomato-transduced E14-Bra-GFP mESCs were used as a positive control with STO feeder cells, 
untransfected (Untft) E14-Bra-GFP mESCs and a negative clone named −B2 comprised the negative 
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Figure 3. Flow cytometry analysis of E2C expression of the selected 3′-HA PCR-screened positive 
clone named +C4. Untransfected (Untft) E14-Bra-GFP mESCs and a negative clone named −B2 was 
used as the negative controls. 10,000 events were counted for each sample. 
2.2. Stemness and Differentiation Potential of Bra-GFP/Rosa26-E2C mESC Reporter Line 
To ensure the knock-in of E2C did not affect self-renewal or differentiation capacity, the cells 
were assessed for the expression of stemness markers and their ability to generate embryoid bodies 
(EBs). To examine the expression of stemness markers, the clone +C4 was immunostained for Oct4 
and Nanog. The results showed strong nuclear expression of these two pluripotent stem cell 
markers, suggesting that the knock-in of E2C had not affected mESC phenotype (Figure 4A). 
Figure 2. E2C expression was examined by fluorescence microscopy in 3′-HA PCR-screened positive
and negative clones. Fluorescence signal was detected within the positive clone named +C4.
tdTomato-transduced E14-Bra-GFP mESCs were used as a positive control with STO feeder cells,
untransfected (Untft) E14-Bra-GFP mESCs and e ti e clone named −B2 comprised the negative
controls. All samples were coun er-stained with the nuclear stain DAPI. Scale bar for all graphs,
100 µm.
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the negative controls. 10,000 events were counted for each sample.
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2.2. Stemness and Differentiation Potential of Bra-GFP/Rosa26-E2C mESC Reporter Line
To ensure the knock-in of E2C did not affect self-renewal or differentiation capacity, the cells
were assessed for the expression of stemness markers and their ability to generate embryoid bodies
(EBs). To examine the expression of stemness markers, the clone +C4 was immunostained for Oct4
and Nanog. The results showed strong nuclear expression of these two pluripotent stem cell markers,
suggesting that the knock-in of E2C had not affected mESC phenotype (Figure 4A).Int. J. Mol. Sci. 2018, 19, 19  5 of 17 
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primitive ectoderm; EEE, extraembryonic endoderm; BM, basement membrane; Cav, cavity. Scale 
bars, 100 µm (A); 400 µm (B). 
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2.3. Quantitative Analysis of E2C Fluorescence Signal In Vivo 
Bra-GFP/Rosa26-E2C mESCs suspended in phosphate-buffered saline (PBS) were injected 
subcutaneously in randomly selected sites in each mouse in an injection volume of 100 µL (number 
of injected cells: 5 × 106, 7.5 × 106 and 10 × 106). Controls comprised 10 × 106 untransfected E14-Bra-GFP 
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E2C fluorescence emitted from the reporter cell line in some injection sites was noticeable in 
vivo immediately following injection. In all experimental groups that were administered with 
Bra-GFP/Rosa26-E2C mESCs, the E2C decreased by 24 h post injection. Detectable fluorescence of 
E2C increased afterwards from this time-point and peaked on day 4 (Figure 5B). Surprisingly, 
although E2C signal intensity decreased between days 4 and 9 (Figure 5B), visual inspection 
suggested that the tumours were increasing in size (Figure 5C), with palpable tumours being present 
by day 4 (Figure 5D). By day 7, several tumours developed reddish-blue discolouration, which was 
probably due to the high degree of vascularisation (Figure 5D′). Despite this, there was no significant 
difference in the fluorescence intensity in tumours generated by the reporter cells and untransfected 
cells (negative controls) within the nine-day growth period (Figure 5B). 
Figure 4. (A) Expression of stemness markers Oct4 and Nanog was confirmed by immunofluorescent
staining of Bra-GFP/Rosa26-E2C mESC clone +C4. All samples were counter-stained with DAPI.
Yellow arrow heads show STO feeder cell nuclei; (B) Differentiation potential of clone +C4 was
confirmed by typical EB formation. Cells were seeded in suspension culture dishes up to day 7.
PrEc, primitive ectoderm; EEE, extraembryonic endoderm; BM, base ent membrane; Cav, cavity.
Scale bars, 100 µm (A); 400 µm (B).
To evaluate whether typical EBs can be formed following the E2C knock-in manipulation,
+C4 mESCs were plated in bacterial petri dishes and cultivated for seven days in EB medium.
Aggregates were observed during the first 24 to 48 h and cavitation was observed in the majority of
EBs by day 7 (Figure 4B). Basement me branes, primitive ectoderm and extraembryonic endoderm
were also identifiable by day 7 in the cavitated EBs, suggesting that the +C4 cells had retained their
ability to differentiate o differ nt lineages (Figure 4B).
2.3. Quantitative Analysis of E2C Fluorescence Signal In Vivo
Bra-GFP/Rosa26-E2C mESCs suspended in phosphate-buffered saline (PBS) were injected
subcutaneously in randomly selected sites in each mouse in an injection volume of 100 µL (number of
injected cells: 5× 106, 7.5× 106 and 10× 106). Controls comprised 10× 106 untransfected E14-Bra-GFP
mESCs (Figure 5A).
Int. J. Mol. Sci. 2018, 19, 19 6 of 17
Int. J. Mol. Sci. 2018, 19, 19  6 of 17 
 
 
Figure 5. (A) IVIS images in vivo at days 0, 1, 4, 7 and 9 post injection of E2C+ cells into the dorsal 
flanks of severe combined immunodeficient (SCID) mice. The emission filter of 605–660 nm 
wavelengths was applied to detect the fluorescent signal generated from Bra-GFP/Rosa26-E2C 
mESCs. The untransfected E14-Bra-GFP cells were used as negative controls. Blue circles show the 
injection sites of cells in the mice. Data are displayed in radiance units (p/s/cm2/sr); (B) Growth 
curves obtained based on the changes of mean region of interest (ROI) radiance post injection. ROI 
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Figure 5. (A) IVIS images in vivo at days 0, 1, 4, 7 and 9 post injection of E2C+ cells into the dorsal flanks
of severe combined immunodeficient (SCID) mice. The emission filter of 605–660 nm wavelengths was
applied to detect the fluorescent signal generated from Bra-GFP/Rosa26-E2C mESCs. The untransfected
E14-Bra-GFP cells were used as negative controls. Blue circles show the injection sites of cells in
the mice. Data are displayed in radiance units (p/s/cm2/sr); (B) Growth curves obtained based on
the changes of mean region of interest (ROI) radiance post injection. ROI radiance was generated
by IVIS software for the time points of day 0, 1, 4, 7 and 9; (C) Growth curves obtained based on
the changes of tumour volume post injection. Tu our volume was calculated based on the manual
measurements of t mours on day 4, 7 and 9; (D) Representative presence of tumours (dashed lines)
from Bra-GFP/Rosa26-E2C ESCs in SCID mice (number 3) that formed from 5 × 106, 7.5 × 106 and
10 × 106 injected cells on day 9 post injecti . The untransfected E14-Bra-GFP cells were used as
a negativ control (10 × 106 cells); (D′) Dissected day-9 tumour that formed fr m 7.5 × 106 injected
Bra-GFP/Rosa26-E2C mESCs howed high degree of vascularisation. M repre ents million (×106).
Error bars represent ±SD (B) and ±SEM (C), respectively (n = 3).
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E2C fluorescence emitted from the reporter cell line in some injection sites was noticeable
in vivo immediately following injection. In all experimental groups that were administered with
Bra-GFP/Rosa26-E2C mESCs, the E2C decreased by 24 h post injection. Detectable fluorescence of E2C
increased afterwards from this time-point and peaked on day 4 (Figure 5B). Surprisingly, although
E2C signal intensity decreased between days 4 and 9 (Figure 5B), visual inspection suggested that the
tumours were increasing in size (Figure 5C), with palpable tumours being present by day 4 (Figure 5D).
By day 7, several tumours developed reddish-blue discolouration, which was probably due to the
high degree of vascularisation (Figure 5D′). Despite this, there was no significant difference in the
fluorescence intensity in tumours generated by the reporter cells and untransfected cells (negative
controls) within the nine-day growth period (Figure 5B).
Quantitative analysis in terms of tumour size and mean region of interest (ROI) radiance are
shown in Tables S1 and S2, respectively. To determine if the emitted fluorescence intensity correlated
with tumour size, tumour volume was measured on days 4, 7 and 9. Tumour growth curves were then
constructed. The measurement data here displayed a distinct increase in tumour size during day 4
and 9. The increase in tumour volume for the 7.5 × 106 dose of E2C reporter mESCs demonstrated
an approximately 4-fold change compared to that of the 5 × 106 cell dose. However, a noticeable
increase in tumour volume was observed in all cases, irrespective of the administration dose (Table S2).
2.4. Histopathology and Immunofluorescence Analyses of Tumours
At the study end point, the mESC tumours were harvested and paraffin sections were analysed
by a pathologist to confirm whether the tumours resembled teratomas. Histologically, tumours were
composed of lobules and nests of primitive cells, focally forming tubular structures with central
lumina and rosette-like structures with some polarisation of lining cells but no lumen. The tubular
formations resembled primitive ectodermal epithelia, and rosette-like structures were reminiscent
of neuroepithelium. In addition, foci of immature mesenchyme and pale islands suggestive of
early chondroid differentiation were evident. There were no well-differentiated elements, nor any
morphologically identifiable yolk sac or trophoblastic differentiation. In a given context it is consistent
with very immature teratoma, featuring ectodermal elements including immature neuroepithelium
and mesodermal elements featuring immature mesenchyme with chondroid islands (Figure 6A,A′).
The tumours also appeared to be well vascularised and contained abundant erythrocytes (Figure 6A′ ′).
To determine if all of the differentiated cells within the tumours continued to express E2C,
and whether the tumour vasculature was derived from the mESCs or the host, immunofluorescence
staining for E2C and the endothelial marker, PECAM-1, was undertaken. The results showed that
most of the tumour cells, including the epithelial and chondrocyte-like cells, expressed E2C, indicating
that the transgene expression was stable over this time-frame. As expected, there was no evidence
of E2C expression in the control tumours (Figure 6B). Platelet endothelial cell adhesion molecule
(PECAM-1) staining showed that none of the endothelial cells within the tumour stained positively for
E2C, indicating that they were all derived from the host (Figure 6B).
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Figure 6. Histopathology and immunofluorescence analyses of tumours derived from the mESCs.
(A–A′′) Haematoxylin and eosin (H&E) staining was performed on paraffin sections prepared from the
day-9 tumours. Arrow heads show epithelial structure (A), thick arrows show chondrocyte-like cells
(A′) and thin arrows show red blood cells (A′′). Dashed lines show the structures of chondrogenic-like
(mesoderm-like) differentiation (A′) and blood vessels (A′′); (B) Immunostaining for E2C (red) and
PECAM-1 (gre n) in tumours derived from Bra-GFP/Rosa26-E2C mESCs or untransfected controls
(Untft). Dual immunostaining of frozen sections prepared from tumours harvested at day 9 showed that
all cells, xc pt the vasculature and blood cells, within the tumours were derived from the E2C+ mESC,
which stained positively for E2C. On the other hand, the endothelial cells within the tumours did not
stain positively for E2C, indicating they were derived from the host animals. Tumours developed from
the untransfected E14-Bra-GFP mESCs were used as controls. Scale bars, 50 µm (A–A′′); 100 µm (B).
3. Discussion
In this study, an E2C-expressing E14-Bra-GFP mESC reporter line (clone +C4) was generated
by knocking-in E2C into the Rosa26 locus. Using the Rosa26 targeting vector generated by Aizawa’s
group [30], which contains long 5′- and 3′-homologous arms and a DT-A counter-selection cassette
against random integration, we achieved a high targeting frequency of 51%. Although targeted
integration at the Rosa26 locus generally introduces only a single copy of the transgene into the
Rosa26 allele [27], leading to lower expression levels than what can be achieved with lentiviral
transduction, there is a lower tendency for transgenes within the Rosa26 locus to become silenced
following differentiation of the mESCs [15]. Therefore, this approach could be more suitable for
tracking cells over the long-term.
To assess the feasibility of imaging the E2C mESC reporter cells in vivo using fluorescence imaging,
we injected three cell doses subcutaneously into SCID mice and imaged over a nine-day time course.
It was found that, even when the animals were imaged immediately following cell administration,
it was not always possible to detect the E2C signal. Thus, the main conclusion from this experiment
is that the E2C is not an effective in vivo reporter in this context (i.e., when introduced as a single
copy into the Rosa26 locus), and imaging the E2C reporters in the internal organs would not be
feasible due to signal attenuation with increasing depth. In contrast to our findings, Christensen and
colleagues were able to detect E2C emitted from tumour cells injected into the rat lung [43]. The likely
explanation is that they used lentiviral technology to generate the reporter cells, which would have
introduced multiple copies of the E2C transgene into each cell. Furthermore, the E2C was expressed
under the strong constitutive cytomegalovirus (CMV) promoter. However, this promoter is not
suitable for constitutive expression in mESCs as it tends to be downregulated during propagation and
differentiation [44].
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In cases where the cells could be detected at day 0, it was found that E2C signal intensity decreased
on day 1 before increasing between days 4 and 7. The reduction in signal at day 1 is probably due
to cell death. SCID mice are deficient in generating T and B lymphocytes and thus are unable to
launch an adaptive immune response. However, they still have an intact innate immune system,
comprising neutrophils, macrophages and natural killer cells that might contribute to the death of
injected mESCs [45]. Another possible reason is that many of the mESCs may simply die due to
the sudden change in their micro-environment, as it is well-known that these cells require specific
culture conditions for their propagation. The increase in fluorescence observed in most tumours
from days 4 to 7 probably reflected the fact that, over this time course, there was an increase in tumour
volume. Interestingly, although the tumour volume continued to increase from days 4 to 7, in most
cases, there was a decrease in fluorescence. This was most likely due to the fact that the tumours
became highly vascularised. H&E staining of tumour sections showed a high number of red blood
cells within the blood vessels. Since haemoglobin plays a major role in photon absorption within the
<650 nm wavelength region, it is likely that E2C fluorescence was partially absorbed by the red blood
cells in the tumours [1].
None of the mice injected with control untransfected mESCs were expected to display any E2C
fluorescence signal. Of note, some background signal was observed in the control tumour of mouse
number 3 on days 4 and 7 post injection. This artefactual signal is likely due to photon scattering and
autofluorescence from the skin abutting the tumour [46].
H&E histopathological examination of the tumours showed that they resembled immature
teratomas, which typically have abundant neuroepithelial cells [47] as well as derivatives of other
germ layers, such as chondrocytes [48]. The abundant epithelial structures observed in the tumours
are likely to resemble either primitive ectoderm epithelia or neuroepithelia. In the developing embryo,
some of the primitive ectoderm cells that do not egress through the primitive streak directly give rise
to neuroepithelial cells [49]. Morphologically, the primitive ectoderm and early neuroepithelial cells
closely resemble each other. Chondrocyte-like cells were also present in the tumours, which would be
consistent with them being immature teratomas. Endothelial cells were also identified lining blood
vessels, but dual immunostaining for E2C and PECAM-1showed that these cells were derived from
the host.
There are numerous reports showing that following subcutaneous implantation or implantation
under the kidney capsule, mESCs will typically form mature teratomas that contain various types of
well-differentiated cells derived from the three germ layers, and can even generate endothelial cells
that form part of the vasculature of the teratoma [50]. However, in these studies the teratomas were
allowed to develop over a four-week period instead of just nine days. Therefore, the fact that teratomas
in this study were immature is probably due to the shorter time that they were allowed to develop in vivo.
To summarise, the results obtained from imaging the reporter cells after subcutaneous
implantation indicate that the emitted E2C fluorescence is weak and it would not be feasible to
image the cells in internal organs such as the kidney. Therefore the focus of future applications of this
reporter cell line could be within the field of in vitro imaging and tracking.
4. Materials and Methods
4.1. Sub-Culture of STO and mESCs
STO feeder cells (ATCC, SCRC-1049) were maintained in 10-cm tissue culture dishes in culture
medium consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) (D6546, Sigma-Aldrich, St. Louis,
MO, USA), 100 mL/L foetal bovine serum (FBS) (Gibco, 10270, Thermo Fisher Scientific, Waltham, MA,
USA), 10 mL/L MEM non-essential amino acid (Sigma-Aldrich, M7145) and 10 mL/L L-glutamine
(Sigma-Aldrich, G7513) at 37 ◦C in a humidified incubator with 5% CO2. Cells were passaged twice
per week at a split ratio of 1:4–1:6 until reaching passage 15. E14-Bra-GFP mESC line used in this study
was a generous gift from Georges Lacaud at the Paterson Institute for Cancer Research, Manchester.
tdTomato-transduced E14-Bra-GFP mESCs were from our in-house stock. mESCs were maintained in
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the 6-well feeder plates in culture medium consisting of DMEM, 150 mL/L FBS (Sigma-Aldrich, F2442),
10 mL/L MEM non-essential amino acid, 10 mL/L L-glutamine, 0.1 mmol/L β-mercaptoethanol
(Gibco, 31350) and 1000 U/mL mouse leukaemia inhibitory factor (mLIF) (ESG1107, Merck Millipore,
Billerica, MA, USA) at 37 ◦C in a humidified incubator with 5% CO2. Cells were passaged every other
day at a split ratio of 1:6–1:10 until reaching passage 40.
4.2. Preparation of Mitomycin-C-Inactivated STO Feeder Cells
24 h prior to the inactivation, the STO culture medium was replaced with fresh medium.
For the inactivation, mitomycin-C (Sigma-Aldrich, M4287) was added to give a final concentration
of 20 µg/mL. The dishes were incubated for 2 h and rinsed with 1× PBS (without Ca2+ and Mg2+).
Cells were collected and plated into gelatinised tissue culture dishes at a density of 5 × 104 cells/cm2.
Prior to plating the mESCs, feeder cells were rinsed once with PBS.
4.3. Preparation and Linearisation of Knock-in Construct
The targeting construct pDEST-ROSA26-E2C was generated by using the pROSA26-STOP-Dest
vector, which was kindly provided by Shinichi Aizawa’s group (RIKEN, Tokyo, Japan) [30].
The pROSA26-STOP-Dest plasmid was derived from pROSA26-Dest and contains homologous
sequences of 8.1 and 3.5 kb, respectively, for reporter gene knock-in into the Rosa26 intronic XbaI
site [25,29]. In addition, it contains a PGK-DTA-pA cassette located outside of the 5′-homologous
sequence for diphtheria toxin expression and counter-selection of mESCs. Briefly, a splice acceptor
cassette, the E2-Crimson open reading frame and an FRT-flanked neomycin phosphotransferase
expression cassette were assembled in the Gateway plasmid pENTR2B (Thermo Fisher Scientific,
A10463). Using the Gateway Clonase system (Thermo Fisher Scientific), this cassette was then
transferred into pROSA26-STOP-Dest as previously described [29]. Finally, the loxP flanked STOP
cassette of the plasmid was removed by transformation into E. coli strain 294-Cre (A111, Gene Bridges,
Heidelberg, Germany), which resulted in a single loxP site remaining 5′of the attB1 site and E2-Crimson
cassette. To linearize the targeting construct, 50 µg pDEST-ROSA26-E2C plasmid DNA was digested
by PvuI (Thermo Fisher Scientific, FD0624). The targeting DNA fragment was separated by gel
electrophoresis and extracted using Wizard® SV Gel and PCR Clean-Up System (A9282, Promega,
Madison, WI, USA). DNA concentrations and purity were determined using a NanoDrop 2000
spectrophotometer (Thermo Fisher Scientific, ND-2000). Where necessary, an ethanol precipitation
was performed to further concentrate linearised DNA. Purified linearised DNA was dissolved in
1× TE buffer.
4.4. Generation of the Knock-in mESC Reporter Line
The E14-Bra-GFP mESCs at passage 7 were expanded in 10 cm feeder dishes in mESC culture
medium. When reaching approximately 70% confluence, cells were trypsinised, pelleted and
resuspended in 1× PBS (without Ca2+ and Mg2+). The cell suspension was mixed with linearised
targeting construct (DNA final concentration 1 µg/µL) and was transferred into cuvettes (800 µL each)
for electroporation (Bio-Rad Gene Pulser with capacitance extender, 240 V, 500 µF, Bio-Rad Laboratories,
Hercules, CA, USA). Cell suspension was transferred to 10 cm feeder dishes and incubated at 37 ◦C in
a humidified incubator with 5% CO2. Two days post electroporation, G418 (Sigma-Aldrich, A1720) was
added into the culture medium at a final concentration of 200 µg/mL, initiating the counter-selection
process. Medium was changed daily and supplemented with G418 until day 9 of the selection.
Viable clones were picked individually and transferred to 96-well non-treated round-bottom plates
containing 1× trypsin/EDTA. Colonies were dissociated and mESC medium was added to neutralise
the trypsinisation. The solution was then transferred to 96-well feeder plates and incubated at 37 ◦C in
a humidified incubator with 5% CO2. After 24 h expansion, cells in each well were trypsinised and
neutralised with mESC medium to reach a total volume of 200 µL per well, half was transferred to
gelatinised 24-well tissue culture plates for screening purpose, whilst half was sealed and frozen at
−80 ◦C for subsequent expansion.
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4.5. Genomic DNA Extraction of mESCs
mESC samples of viable clones were collected in 1.5 mL microfuge tubes and resuspended in
lysis buffer containing 100 µg/mL Proteinase K (Sigma-Aldrich, P6556) for an incubation at 55 ◦C
overnight. One volume of 2-propanol was added followed by centrifugation at 16,000× g for 1 min to
obtain the genomic DNA (gDNA) pellets. gDNA pellets were washed twice with 70% ethanol and air
dried. They were then re-dissolved in 1× TE buffer at 4 ◦C overnight followed by 65 ◦C for 15 min.
DNA concentrations and purity was measured using the NanoDrop 2000 spectrophotometer (Thermo
Fisher Scientific).
4.6. 3′-Homology Arm PCR Analysis
3′- homology arm (HA) PCR analyses were performed on the gDNAs of viable colonies using
a GoTaq® Long PCR reaction system (Promega, M4021) according to the manufacturer’s manual.
gDNA template from untransfected E14-Bra-GFP mESCs served as a negative control. A non-template
control was also included where template gDNA was substituted by nuclease-free water. PCR primer
sequences were: 5′-GGCTTCTGAGGCGGAAAGA-3′ (forward); 5′-CAACAATCAGCCTAAGGTAG-3′
(reverse). The PCR programme was set up as follows: hot start at 95 ◦C for 2 min, followed by PCR
steps comprising denaturation at 94 ◦C for 30 s, annealing at 65 ◦C for 30 s, elongation at 65 ◦C for
4 min, and final extension at 72 ◦C for 10 min, for 30 cycles. Products were examined on a 0.8%
agarose gel.
4.7. Analysis of E2C Expression in the PCR Screened Positive Clones with Fluorescence Microscopy
Screened clones were plated on gelatin for 48 h and then re-plated on gelatinised eight-chamber
slides. When reaching required colony size, they were fixed with 4% paraformaldehyde (PFA)
followed by counter-staining with 4′,6-diamidino-2-phenylindole (DAPI) (Thermo Fisher Scientific,
D1306, 1/100,000) as for immunofluorescence staining. Slides were examined by the Leica DM2500
(Leica, Wetzlar, Germany) fluorescence microscope with the 561 nm laser and data were acquired
by the Leica Application Suite (LAS, Leica) integrated software. STO feeder cells as well as
untransfected and tdTomato-transduced E14-Bra-GFP mESCs were included as negative and positive
controls, respectively.
4.8. Flow Cytometry Analysis
Single cell suspension in 1× PBS (1 × 106 cells/mL) was acquired from Bra-GFP/Rosa26-E2C cells.
Prior to the analysis, the suspension was filtered using a 40-µm strainer (BD Falcon, 352340, Hunter
Scientific, Saffron Walden, UK). The percentage of E2C+ cells were analysed using a BD FACSCanto
(BD Biosciences, San Jose, CA, USA) flow cytometer. Untransfected E14-Bra-GFP mESCs were used as
a negative control. Data output was performed using BD FACSDiva (version 6.1.3) software.
4.9. Embryoid Body Formation
To form EBs, early passages of mESCs maintained in STO feeder plates were sub-cultured in
feeder-free gelatinised tissue culture plates for 48 h. Cells were collected and resuspended in mouse
EB medium consisting of DMEM, 100 mL/L FBS (Sigma-Aldrich, F2442), 10 mL/L MEM non-essential
amino acid, 10 mL/L L-glutamine and 0.1 mmol/L β-mercaptoethanol. Cells were then plated in
90-mm bacterial petri dishes (Sterilin, 101VR20, Thermo Fisher Scientific) at the seeding density of
1.25 × 105 cells/mL. The EBs were maintained for up to 9 days. Medium was changed every other
day. Each EB dish was split 1:2 on day 3 post plating. EB morphology was examined at days 4 and 7.
Experiments were performed in three independent biological replicates.
4.10. Administration and Imaging of Bra-GFP/Rosa26-E2C
Bra-GFP/Rosa26-E2C and untransfected E14-Bra-GFP mESCs were harvested from the feeder
plates and expanded in 10 cm gelatinised tissue culture dishes and cultured for 48 h to reach the
required density. The cell resuspensions in 1× PBS were stored on ice immediately prior to in vivo
Int. J. Mol. Sci. 2018, 19, 19 12 of 17
administration. Three female CB17 severe combined immunodeficient (SCID) mice (Charles River,
Wilmington, MA, USA) were housed in accordance with the guidelines. Experiments were performed
following the approved guidelines under a UK Home Office licence (Licence Number: 70/8741;
Approval Date: 06/10/2015) under the Animals (Scientific Procedures) Act 1986 and approved by the
University of Liverpool Animal Ethics Committee. At the age of 8–10 weeks old, mice were used for
mESCs injection. Animals were anaesthetised with isoflurane, shaved and depilated to remove fur
from the torso. mESCs in 100 µL of 1× PBS were administered to the dorsal flank of individual mouse
via subcutaneous injection at 4 different positions (top left, top right, bottom left and bottom right
of the torso). The following doses of 10, 7.5 and 5 × 106/100 µL Bra-GFP/Rosa26-E2C mESCs were
injected into three of the positions in a random manner. 10 × 106/100 µL untransfected E14-Bra-GFP
mESCs were individually injected alongside the Bra-GFP/Rosa26-E2C engrafts in the same mouse as
negative controls. The implantation pattern was in keeping with the suggested UK NC3Rs (National
Centre for the Replacement, Refinement, and Reduction of Animals in Research) experimental design,
which recommends randomisation to ensure that observed effects on the growth of the implanted cells
is not site-dependent. Experiments were performed in three independent biological replicates. Data of
the signal intensity in terms of the radiance measured at the regions of interest (ROI) were acquired on
days 0, 1, 4, 7 and 9 post injection using the IVIS® Spectrum In Vivo Imaging System (PerkinElmer,
Waltham, MA, USA) and analysed with its Living Image® software (version 4.5).
4.11. Tumour Volume Measurement
Following the injection, the tumour size was measured using a digital calliper on day 4, 7 and 9
in terms of the length, width and height of the tumours. The length was measured in the direction
of the dorsal longitude; the width was measured along the dorsal latitude; and the height was
measured perpendicularly in between the surface of the back and the upper surface of the tumours.
A mathematical model of solid tumour volume calculation has previously been constructed based on
the assumption that tumours are hemi-ellipsoid in 3D shape. Therefore, the volume is calculated from
the measurements of tumour length, width and height using the following equation [51,52]:
V = pilwh/6 (1)
where V is the tumour volume, and l, w, h are the length, width, and height of the tumour, respectively.
4.12. Tumour Fixation
Mice were sacrificed on day 9, when the tumours reached the size limit according to the Home
Office guidelines. Tumours were harvested immediately afterwards and fixed with 4% PFA at 4 ◦C
overnight. If necessary, larger tumours were vertically cut into small pieces prior to fixation.
4.13. Tumour Histopathological Analysis
Fixed tumours were rinsed with 1× PBS and transferred to 70% ethanol followed by a general
paraffin embedding process [53]. Then 5-µm sections were stained with haematoxylin and eosin (H&E)
followed by histopathological examination.
4.14. Immunofluorescence Staining of Stemness Markers
Bra-GFP/Rosa26-E2C and untransfected E14-Bra-GFP mESC lines were sub-cultured from STO
feeder layers to gelatinised tissue culture dishes for 48 h. They were then plated into gelatinised
8-chamber slides or 35 mm dishes and fixed with 4% PFA when reaching the required density. Samples
were blocked in 10% serum solution containing 0.1% Triton-X 100 at room temperature for 1 h and
then incubated with the primary antibody solutions (Oct4: Santa Cruz, CA, USA, sc-5279, 1/500;
Nanog: Abcam, Cambridge, UK, ab80892, 1/500) at 4 ◦C overnight. They were rinsed with 1× PBS
and incubated with Alexa Fluor®-labelled secondary antibody solution (Thermo Fisher Scientific,
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1/1000) at room temperature for 2 h. All samples were then counter-stained with DAPI at room
temperature for 15 min. Slides were mounted with DAKO fluorescent mounting medium (S3023,
Agilent Technologies, Santa Clara, CA, USA) and sealed by nail polish. Controls were also included to
check for non-specific binding of secondary antibodies, and these comprised samples where primary
antibodies were omitted. Data were acquired using a Leica DM2500 or DMIRB fluorescence microscope
and the Leica Application Suite (LAS, Leica) integrated software.
4.15. Immunofluorescence Staining of Frozen Tumour Sections
Fixed tumours were rinsed with 1× PBS followed by a concessive immersing process of 15% and
30% sucrose at 4 ◦C overnight, respectively. Tumours were then embedded with embedding resin
and frozen in cryostat section machine. Then 10-µm sections were blocked in 10% serum solution(s)
at room temperature for 1 h followed by incubation with E2-Crimson (Clonetech, 632496, 1/1000,
Takara Bio USA, Inc., Mountain View, CA, USA) and PECAM-1 (BD Pharmingen, 550274, 1/1000,
Becton, Dickinson and Company, Oxford, UK) primary antibodies at 4 ◦C overnight. They were rinsed
with 1× PBS and then incubated with Alexa Fluor®-labelled secondary antibody solutions (Thermo
Fisher Scientific, 1/1000) at room temperature for 2 h. The remaining protocols followed those for
stemness markers staining in 4.14. Data were acquired using a Leica DM2500 fluorescence microscope
and the Leica Application Suite (LAS, Leica) integrated software.
4.16. Statistical Analysis
Data were analysed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA, version
5.01) and processed data were plotted by GraphPad Prism. For the statistical analysis of all the data,
the same number/replicates were analysed. Basic functions used were: mean, standard deviation (SD),
standard error of the mean (SEM) and Student’s t-test.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/19/1/19/s1.
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Figure A1. 0.8% agarose gel electrophoresis of a total of 35 viable clones screened by 3′-HA PCR. 500 
ng gDNA templates (numbered as 1 to 35) were amplified at the annealing temperature of 65 °C for 
30 cycles, with gDNA template from untransfected (Untft) E14-Bra-GFP mESCs cultured on gelatine 
as a negative control. A non-template control (NTC) was also included where template gDNA was 
substituted by nuclease-free water. Eighteen out of 35 viable clones show bright positive bands and 
three show weaker bands (indicated by asterisks) of the correct size of 3380 bp. L, 1 kb ladder. 
  
Figure A1. 0.8% agarose gel electrophoresis of a total of 35 viable clones screened by 3′-HA PCR.
500 ng gDNA templates (numbered as 1 to 35) were amplified at the annealing temperature of 65 ◦C for
30 cycles, with gDNA template from untransfected (Untft) E14-Bra-GFP mESCs cultured on gelatine
as a negative control. A non-template control (NTC) was also included where template gDNA was
substituted by nuclease-free water. Eighteen out of 35 viable clones show bright positive bands and
three show weaker bands (indicated by asterisks) of the correct size of 3380 bp. L, 1 kb ladder.
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